Stock Analiz

AVITA Medical, Inc. RCEL

Medical/Dental Instruments · data as of November 13, 2026

$15.63Market cap $491M
Open the interactive analysis →

AVITA Medical, Inc. (RCEL) is a healthcare company listed in the US with a market value of about $491M. In the twelve months to September 30, 2026 it had revenue of $85M and net income of -$36M, a net margin of -42.7%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 38% a year, a 5-year average ROIC of -57%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 72% below the current price.

About AVITA Medical

AVITA Medical is listed in the US and classified in medical/dental instruments. Revenue went from $692673 in 2017 to $72M in 2025, growth of about 78.6% a year. It was profitable in 0 of the last 9 years in our data. It spends 29% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record2/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S5.8
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-4.1%
Shareholder yield0.0%
Intrinsic value vs. price−72%

Growth and quality

Revenue growth (1 yr)11.5%
Revenue growth (5 yrs, per year)38.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-80.6%
ROIC (5-yr avg.)-56.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$85M$72M$64M$50M$34M$29M$14M$5M$929000$692673
Net income-$36M-$49M-$62M-$35M-$27M-$27M-$42M-$25M-$13M-$9M
Free cash flow-$20M-$32M-$58M-$39M-$20M-$27M-$23M-$20M-$13M-$7M
EPS (diluted)$-1.18$-1.55$-1.97$-1.13$-0.85$-0.85$-1.34$-0.80$-0.41$-0.28
Net margin-42.7%-67.8%-96.3%-70.6%-77.5%-90.9%-294.7%-458.6%-1370.8%-1277.0%
ROIC—-114.3%-88.6%-36.8%-25.4%-17.9%-45.0%-107.0%-91.0%-224.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $20.70, 32% above the current price; targets range from $19.65 to $21.83; the consensus rating is “Strong buy”; expected EPS is $0.42 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is AVITA Medical stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 72% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does AVITA Medical pay a dividend?

Not currently.

Is AVITA Medical a good stock to buy?

We do not give buy or sell advice. AVITA Medical scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.